These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 10380754)

  • 1. Cleavage of double-stranded copy RNA by RNase 1 and RNase T1 provides a robust means to detect p53 gene mutations in clinical specimens.
    Prescott J; Patel H; Tillman S; McHugh T; Ralph D
    Electrophoresis; 1999 Jun; 20(6):1149-61. PubMed ID: 10380754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NIRCA: a rapid robust method for screening for unknown point mutations.
    Goldrick MM; Kimball GR; Liu Q; Martin LA; Sommer SS; Tseng JY
    Biotechniques; 1996 Jul; 21(1):106-12. PubMed ID: 8816244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensitivity and specificity of p53 protein detection by immunohistochemistry in patients with urothelial bladder carcinoma.
    Salinas-Sánchez AS; Atienzar-Tobarra M; Lorenzo-Romero JG; Sánchez-Sánchez F; Giménez-Bachs JM; Donate-Moreno MJ; Pastor-Navarro H; Hernández-Millán I; Segura-Martín M; Escribano-Martínez J
    Urol Int; 2007; 79(4):321-7. PubMed ID: 18025850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective detection of inactivating mutations of the tumor suppressor gene p53 in bladder tumors.
    Pfister C; Flaman JM; Martin C; Grise P; Frebourg T
    J Urol; 1999 Jun; 161(6):1973-5. PubMed ID: 10332483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RNase cleavage-based methods for mutation/SNP detection, past and present.
    Goldrick MM
    Hum Mutat; 2001 Sep; 18(3):190-204. PubMed ID: 11524730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 mutations as a marker of malignancy in bladder washing samples from patients with bladder cancer.
    Phillips HA; Howard GC; Miller WR
    Br J Cancer; 2000 Jan; 82(1):136-41. PubMed ID: 10638980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue polypeptide antigen (TPA) in comparison with mutations of tumour suppressor gene P53 (TP53) in patients with bladder cancer.
    Ecke TH; Lenk SV; Schlechte HH; Loening SA
    Anticancer Res; 2003; 23(2A):957-62. PubMed ID: 12820330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screen p53 mutations in hepatocellular carcinoma by FASAY: a novel splicing mutation.
    Wu XM; Fu JG; Ge WZ; Zhu JY; Wang JY; Zhang W; Qian W; Huo KK
    J Zhejiang Univ Sci B; 2007 Feb; 8(2):81-7. PubMed ID: 17266182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 Immunostaining guided laser capture microdissection (p53-LCM) defines the presence of p53 gene mutations in focal regions of primary prostate cancer positive for p53 protein.
    Griewe GL; Dean RC; Zhang W; Young D; Sesterhenn IA; Shanmugam N; McLeod DG; Moul JW; Srivastava S
    Prostate Cancer Prostatic Dis; 2003; 6(4):281-5. PubMed ID: 14663467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alport syndrome. Molecular genetic aspects.
    Hertz JM
    Dan Med Bull; 2009 Aug; 56(3):105-52. PubMed ID: 19728970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer.
    George B; Datar RH; Wu L; Cai J; Patten N; Beil SJ; Groshen S; Stein J; Skinner D; Jones PA; Cote RJ
    J Clin Oncol; 2007 Dec; 25(34):5352-8. PubMed ID: 18048815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative detection of mutant alleles of the K-ras gene with minor groove binder-conjugated fluorogenic DNA probes.
    Itabashi T; Maesawa C; Uchiyama M; Higuchi T; Masuda T
    Int J Oncol; 2004 Mar; 24(3):687-96. PubMed ID: 14767554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of clinically relevant point mutations by a novel piezoelectric biosensor.
    Dell'Atti D; Tombelli S; Minunni M; Mascini M
    Biosens Bioelectron; 2006 Apr; 21(10):1876-9. PubMed ID: 16388945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid and sensitive p53 alteration analysis in biopsies from lung cancer patients using a functional assay and a universal oligonucleotide array: a prospective study.
    Fouquet C; Antoine M; Tisserand P; Favis R; Wislez M; Commo F; Rabbe N; Carette MF; Milleron B; Barany F; Cadranel J; Zalcman G; Soussi T
    Clin Cancer Res; 2004 May; 10(10):3479-89. PubMed ID: 15161705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spectrum of p53 mutations in biopsies from breast cancer patients selected for preoperative chemotherapy analysed by the functional yeast assay to predict therapeutic response.
    Deissler H; Kafka A; Schuster E; Sauer G; Kreienberg R; Zeillinger R
    Oncol Rep; 2004 Jun; 11(6):1281-6. PubMed ID: 15138567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of mutations to different structural and functional regions of the p53 gene in breast cancer.
    Powell B; Soong R; Iacopetta B; Seshadri R; Smith DR
    Clin Cancer Res; 2000 Feb; 6(2):443-51. PubMed ID: 10690522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer.
    Smith ND; Rubenstein JN; Eggener SE; Kozlowski JM
    J Urol; 2003 Apr; 169(4):1219-28. PubMed ID: 12629332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensitive detection of p53 mutation: analysis by direct sequencing and multisequence analysis.
    Rozemuller EH; Kropveld A; Kreyveld E; Leppers FG; Scheidel KC; Slootweg PJ; Tilanus MG
    Cancer Detect Prev; 2001; 25(2):109-16. PubMed ID: 11341345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topoisomerase IIalpha gene expression is regulated by the p53 tumor suppressor gene in nonsmall cell lung carcinoma patients.
    Liu D; Huang CL; Kameyama K; Hayashi E; Yamauchi A; Sumitomo S; Yokomise H
    Cancer; 2002 Apr; 94(8):2239-47. PubMed ID: 12001123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A rapid fluorescence based multiplex polymerase chain reaction--single-strand conformation polymorphism method for p53 mutation detection.
    Berggren P; Steineck G; Hemminki K
    Electrophoresis; 2000 Jul; 21(12):2335-42. PubMed ID: 10939443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.